Guangdong Association of Clinical Trials

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 1997-01-01

Employees: -

Market Cap: -

Website: http://gdaids.org

Clinical Trials

A Non-interventional Retrospective Study on Overall Survival in Completely Resected Chinese NSCLC Patients With Adenocarcinoma Histology- ICAN Extension Study

Conditions: Overall Survival

First Posted Date: 2018-09-06

Last Posted Date: 2018-09-06

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 571

Registration Number: NCT03658928

The Impact of Neurocognitive Function in Patients With Multiple Brain Metastases Receiving Whole Brain Radiation Therapy

Conditions: Brain Metastases

First Posted Date: 2018-08-13

Last Posted Date: 2018-08-13

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 125

Registration Number: NCT03626818

Locations: 🇨🇳
Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China

A Real World Study Based on NGS (TRUMPRWS)

Recruiting

Conditions: Non-Small Cell Carcinoma of Lung, TNM Stage 4

First Posted Date: 2018-07-30

Last Posted Date: 2020-02-07

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 2700

Registration Number: NCT03605602

Locations: 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China

Phase II Umbrella Study Directed by Next Generation Sequencing

Phase 2

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Avitinib Maleate
Drug: Afatinib
Drug: Pyrotinib Maleate
Drug: Pirotinib
Drug: Nimotuzumab
Drug: Sintilimab
Drug: Crizotinib
Drug: X-396
Drug: AZD3759
Drug: Gemcitabine
Drug: Pemetrexed
Drug: Cisplatin
Drug: Chidamide
Drug: Carboplatin

First Posted Date: 2018-07-02

Last Posted Date: 2022-12-06

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 400

Registration Number: NCT03574402

Locations: 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China

Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy

Not Applicable

Recruiting

Conditions: Lung Neoplasms

Interventions: Other: local consolidative treatment

First Posted Date: 2017-02-08

Last Posted Date: 2020-07-23

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 60

Registration Number: NCT03046316

Locations: 🇨🇳
Guangdong General Hospital, Guangzhou, Guagndong, China

PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC Patients

Conditions: Small Cell Lung Cancer, Polygonal Type

First Posted Date: 2017-01-24

Last Posted Date: 2017-01-24

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 155

Registration Number: NCT03029858

Locations: 🇨🇳
Fujian Principal Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳
The first Affiliated hospital of Zhejiang University，Respiratory dept., Hangzhou, Zhejiang, China

and more 9 locations

Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Neoplasm Malignant

Interventions: Drug: Vinorelbine Oral

First Posted Date: 2016-12-07

Last Posted Date: 2020-03-12

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 45

Registration Number: NCT02985203

Locations: 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China

Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations

Phase 3

Conditions: NSCLC

Interventions: Drug: Bevacizumab
Drug: Erlotinib

First Posted Date: 2016-05-03

Last Posted Date: 2018-06-25

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 311

Registration Number: NCT02759614

Locations: 🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

Phase 2

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2016-04-01

Last Posted Date: 2020-02-12

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 150

Registration Number: NCT02725918

Locations: 🇨🇳
Guangdong Lung cancer institute, Guangzhou, Guangdong, China

Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer

Phase 3

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Docetaxel
Drug: Nedaplatin
Drug: Cisplatin

First Posted Date: 2015-12-31

Last Posted Date: 2015-12-31

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 488

Registration Number: NCT02643407

Locations: 🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy